Company: INDP
Filing Date: 2025-01-14
Form Type: 8-K
Source: 0001493152-25-002145
Chunk: 0

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-01-14
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item       Entry                                  

On
January 12, 2025, Indaptus Therapeutics, Inc., a Delaware corporation (the “ Company”), entered into securities purchase agreements
(the “ Purchase Agreements”) with certain institutional and accredited investors (the “ Purchasers”) in a private
placement transaction for aggregate gross proceeds of $2,246,500. The Purchase Agreements provide for the sale and issuance in
a private placement offering by the Company of an aggregate of: (i) 2,109,383 shares (the “ Shares”) of the Company’s
common stock, $0.01 par value (the “ Common Stock”); and (ii) warrants to purchase 2,109,383 shares of Common Stock
(the “ Warrants”). The Company intends to use the net proceeds from the private placement to fund its research and development
activities and for working capital and general corporate purposes. The private placement is expected to close on or about January 15,
2025, subject to satisfaction of customary closing conditions.

The
Shares and Warrants are being sold on a combined basis for consideration of $1.065 for one Share and a Warrant to purchase one share
of Common Stock. The Warrants will have an exercise price of $0.94 per Share.

The
Shares, the Warrants and the shares of Common Stock issuable upon the exercise of the Warrants (the “ Warrant Shares”) were
not registered under the Securities Act of 1933, as amended (the “ Securities Act”), and were offered pursuant to the exemption
provided in Section 4(a)(2) under the Securities Act and/or Rule 506(b) promulgated thereunder.

The
Warrants are immediately exercisable upon issuance and will expire five years following the date of issuance. The Warrants contain standard
adjustments to the exercise price including for stock splits, stock dividends and reorganizations. In lieu of making the cash payment
otherwise contemplated to be made upon exercise in payment of the aggregate exercise price, the holder may, in
the event the Warrant Shares are not registered under the Securities Act

Pursuant
to the Purchase Agreements, the Company has agreed to file a registration statement within 60 days of the date of the Purchase Agreements
to register the Shares and Warrant Shares for resale. The Company has also agreed to use commercially reasonable efforts to cause such
registration statement to become effective within 90 days following the closing date of the offering and to use commercially reasonable